JNJ stock projects earnings impact from CAR-T deal (NYSE:JNJ)

May 2, 2023

The Janssen unit of Johnson & Johnson (NYSE:JNJ) announced Tuesday that its parent company will incur a ~10c annual negative impact on 2023 and 2024 earnings per share as a result of a deal with Cellular Biomedicine Group (CBMG) for CAR T-cell therapies.…

This data comes from the media intelligence and smart news insights monitoring platform.

Original URL: Click here to visit original article